Pipeline > Oncology

 

We have a number of discovery programs in oncology. As many key proteins controlling the tumour micro-environment bind to glycans, there is great potential to apply our expertise to the discovery of glycan-binding decoy proteins in oncology.  

ProtAffin in the News

31 March 2012

CEO Jason Slingsby interviewed on Stock News Now (SNN) at the Biotech Showcase 2012 event Website

16 February 2012

CEO Jason Slingsby speaks at a recent SCRIP Round Table. Website

Complete News Archive »